Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Celltrion Sees ‘Record-High Revenue’ With Increasing Infliximab Sales

As Company Plans To Launch One Biological Product Every Year

Executive Summary

South Korea’s Celltrion has delivered a strong fourth quarter in FY21 based on the increase in infliximab sales across all markets as well as a contribution from its Regkirona COVID-19 treatment. The company expects modest top-line growth to continue by launching at least one biological product every year. 

You may also be interested in...



Eurofarma Biosimilars Deal Broadens Access To Latin America For Henlius

Shanghai Henlius Biotech has announced a licensing deal for three biosimilars – bevacizumab, rituximab and trastuzumab – with Brazil’s Eurofarma. The agreement, which could be worth as much as $50.5m, gives the Chinese company enhanced access to Latin America as it continues to broaden its global footprint.

Celltrion Launches Higher-Strength Yuflyma Adalimumab In Canada

Months after it received approval from local regulator Health Canada, Celltrion’s Yuflyma high-concentration adalimumab biosimilar is now available in the North American market, setting up a potential rivalry with Alvotech and its marketing partner JAMP Pharma.

Celltrion Celebrates Brazilian Tender Win For Infliximab

Celltrion’s Remsima infliximab biosimilar has won a Brazilian federal tender as well as several individual state bids, following earlier awards for the Korean firm’s Truxima (rituximab) and Herzuma (trastuzumab) biosimilars.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

GB151729

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel